Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk

Hypertension Research

Volumn 30, Issue 4, 2007, Pages 285-293

  Dawood, Tye ^a,b   Lambert, Elisabeth A ^a   Barton, David A ^a,b   Laude, Dominique ^c   Elghozi, Jean Luc ^c   Esler, Murray D ^a,b   Haikerwal, Deepak ^a   Kaye, David M ^a   Hotchkin, Elodie J ^a   Lambert, Gavin W ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Antidepressants; Autonomic nervous system; Depressive disorder; Inflammation; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TARGETING; FEMALE; HEART RATE VARIABILITY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MALE; PRESSORECEPTOR REFLEX; PROTEIN BLOOD LEVEL; PULSE PRESSURE; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VAGUS NERVE STIMULATION;

ADULT; AUTONOMIC NERVOUS SYSTEM; BAROREFLEX; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 34249082087     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.285     Document Type: Article

References (44)

1. Barefoot JC, Schroll M: Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-1980.
2. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML: Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000; 160: 1261-1268.
3. Bunker SJ, Colquhoun DM, Esler MD, et al: "Stress" and coronary heart disease: psychosocial risk factors. Med J Aust 2003; 178: 272-276.
4. Rosengren A, Hawken S, Ounpuu S, et al: Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 953-962.
5. Walther T, Wessel N, Baumert M, Stepan H, Voss A, Faber R: Longitudinal analysis of heart rate variability in chronic hypertensive pregnancy. Hypertens Res 2005; 28: 113-118.
6. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ, ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351: 478-484.
7. Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580-592.
8. Alesci S, Martinez PE, Kelkar S, et al: Major depression is associated with significant diurnal elevations in plasma II-6 levels, a shift of its circadian rhythm, and loss of physiologic complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005; 90: 2522-2530.
9. Maes M, Meltzer HY, Bosmans E, et al: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-309.
10. Wong ML, Xie B, Beatini N, et al: Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A 2000; 97: 8681-8686.
11. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al: Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004; 25: 492-499.
12. Blake GJ, Rifai N, Buring JE, Ridker PM: Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
13. Ridker PM, Cannon CP, Morrow D, et al: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
14. Schlienger RG, Fischer LM, Jick H, Meier CR: Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf 2004; 27: 1157-1165.
15. Guzzetti S, Piccaluga E, Casati R, et al: Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens 1988; 6: 711-717.
16. Beske SD, Alvarez GE, Ballard TP, Davy KP: Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol 2002; 282: H630-H635.
17. Ziegler D, Laude D, Akila F, Elghozi JL: Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clin Auton Res 2001; 11: 369-376.
18. Lambert EA, Thompson J, Schlaich M, et al: Sympathetic and cardiac baroreflex function in panic disorder. J Hypertens 2002; 20: 2445-2451.
19. Constant I, Laude D, Murat I, Elghozi JL: Pulse rate variability is not a surrogate for heart rate variability. Clin Sci (Lond) 1999; 97: 391-397.
20. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology: Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
21. Pagani M, Lombardi F, Guzzetti S, et al: Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986; 59: 178-193.
22. Robbe HW, Mulder LJ, Ruddel H, Langewitz WA, Veldman JB, Mulder G: Assessment of baroreceptor reflex sensitivity by means of spectral analysis. Hypertension 1987; 10: 538-543.
23. Parati G, Frattola A, Di Rienzo M, Castiglioni P, Pedotti A, Mancia G: Effects of aging on 24-h dynamic baroreceptor control of heart rate in ambulant subjects. Am J Physiol 1995; 268: H1606-H1612.
24. Tracey KJ: The inflammatory reflex. Nature 2002; 420: 853-859.
25. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS: Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 562-564.
26. Krittayaphong R, Cascio WE, Light KC, et al: Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med 1997; 59: 231-235.
27. Pitzalis MV, Iacoviello M, Todarello O, et al: Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction. Am Heart J 2001; 141: 765-771,
28. Watkins LL, Grossman P, Krishnan R, Blumenthal JA: Anxiety reduces baroreflex cardiac control in older adults with major depression. Psychosom Med 1999; 61: 334-340.
29. Schwartz PJ, Zaza A, Pala M, Locati E, Beria G, Zanchetti A: Baroreflex sensitivity and its evolution during the first year after myocardial infarction. J Am Coll Cardiol 1988; 12: 629-636.
30. Ceglia I, Acconcia S, Fracasso C, Colovic M, Caccia S, Invernizzi RW: Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol 2004; 142: 469-478.
31. Popik P: Preclinical pharmacology of citalopram. J Clin Psychopharmacol 1999; 19: 4S-22S.
32. Itoh H, Alper RH, Bunag RD: Baroreflex changes produced by serotonergic or catecholaminergic lesions in the rat nucleus tractus solitarius. J Pharmacol Exp Ther 1992; 261: 225-233.
33. Merahi N, Orer HS, Laporte AM, Gozlan H, Hamon M, Laguzzi R: Baroreceptor reflex inhibition induced by the stimulation of serotonin3 receptors in the nucleus tractus solitarius of the rat. Neuroscience 1992; 46: 91-100.
34. Blake GJ, Ridker PM: Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-294.
35. Pearson TA, Mensah GA, Alexander RW, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
36. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
37. Safar ME: Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Curr Opin Nephrol Hypertens 2001; 10: 257-261.
38. Tanaka M, Babazono T, Takeda M, Iwamoto Y: Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res 2006; 29: 345-352.
39. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999; 100: 354-360.
40. Pacher P, Ungvari Z: Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001; 57: 469-471.
41. Meier CR, Schlienger RG, Jick H: Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52: 179-184.
42. Sauer WH, Berlin JA, Kimmel SE: Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-36.
43. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-2599.
44. Manfredini R, Portaluppi F, Grandi E, Fersini C, Gallerani M: Out-of-hospital sudden death referring to an emergency department. J Clin Epidemiol 1996; 49: 865-868.